In a controlled trial of community-acquired pneumonia performed in the U.S., azithromycin (500 mg as a single daily dose by the intravenous route for 2 to 5 days, followed by 500 mg/day by the oral route to complete 7 to 10 days therapy) was compared to cefuroxime (2,250 mg/day in three divided doses by the intravenous route for 2 to 5 days followed by 1,000 mg/day in two divided doses by the oral route to complete 7 to 10 days therapy), with or without erythromycin. For the 291 patients who were evaluable for clinical efficacy, the clinical outcome rates, i.e., cure, improved, and success (cure + improved) among the 277 patients seen at 10 to 14 days post-therapy were as follows:
| Clinical Outcome | Azithromycin | Comparator |
|---|---|---|
| Cure | 46% | 44% |
| Improved | 32% | 30% |
| Success (Cure + Improved) | 78% | 74% |
In a separate, uncontrolled clinical and microbiological trial performed in the U.S., 94 patients with community-acquired pneumonia who received azithromycin in the same regimen were evaluable for clinical efficacy. The clinical outcome rates, i.e., cure, improved, and success (cure + improved) among the 84 patients seen at 10 to 14 days post-therapy were as follows:
| Clinical Outcome | Azithromycin |
|---|---|
| Cure | 60% |
| Improved | 29% |
| Success (Cure + Improved) | 89% |
Microbiological determinations in both trials were made at the pre-treatment visit and, where applicable, were reassessed at later visits. Serological testing was done on baseline and final visit specimens. The following combined presumptive bacteriological eradication rates were obtained from the evaluable groups:
Combined Bacteriological Eradication Rates for Azithromycin:
| (at last completed visit) | Azithromycin |
|---|---|
| |
| S. pneumoniae | 64/67 (96%)* |
| H. influenzae | 41/43 (95%) |
| M. catarrhalis | 9/10 (90%) |
| S. aureus | 9/10 (90%) |
The presumed bacteriological outcomes at 10 to 14 days post-therapy for patients treated with azithromycin with evidence (serology and/or culture) of atypical pathogens for both trials were as follows:
| Evidence of Infection | Total | Cure | Improved | Cure + Improved |
|---|---|---|---|---|
| Mycoplasma pneumoniae | 18 | 11 (61%) | 5 (28%) | 16 (89%) |
| Chlamydia pneumoniae | 34 | 15 (44%) | 13 (38%) | 28 (82%) |
| Legionella pneumophila | 16 | 5 (31%) | 8 (50%) | 13 (81%) |
In a controlled trial of community-acquired pneumonia performed in the U.S., azithromycin (500 mg as a single daily dose by the intravenous route for 2 to 5 days, followed by 500 mg/day by the oral route to complete 7 to 10 days therapy) was compared to cefuroxime (2,250 mg/day in three divided doses by the intravenous route for 2 to 5 days followed by 1,000 mg/day in two divided doses by the oral route to complete 7 to 10 days therapy), with or without erythromycin. For the 291 patients who were evaluable for clinical efficacy, the clinical outcome rates, i.e., cure, improved, and success (cure + improved) among the 277 patients seen at 10 to 14 days post-therapy were as follows:
| Clinical Outcome | Azithromycin | Comparator |
|---|---|---|
| Cure | 46% | 44% |
| Improved | 32% | 30% |
| Success (Cure + Improved) | 78% | 74% |
In a separate, uncontrolled clinical and microbiological trial performed in the U.S., 94 patients with community-acquired pneumonia who received azithromycin in the same regimen were evaluable for clinical efficacy. The clinical outcome rates, i.e., cure, improved, and success (cure + improved) among the 84 patients seen at 10 to 14 days post-therapy were as follows:
| Clinical Outcome | Azithromycin |
|---|---|
| Cure | 60% |
| Improved | 29% |
| Success (Cure + Improved) | 89% |
Microbiological determinations in both trials were made at the pre-treatment visit and, where applicable, were reassessed at later visits. Serological testing was done on baseline and final visit specimens. The following combined presumptive bacteriological eradication rates were obtained from the evaluable groups:
Combined Bacteriological Eradication Rates for Azithromycin:
| (at last completed visit) | Azithromycin |
|---|---|
| |
| S. pneumoniae | 64/67 (96%)* |
| H. influenzae | 41/43 (95%) |
| M. catarrhalis | 9/10 (90%) |
| S. aureus | 9/10 (90%) |
The presumed bacteriological outcomes at 10 to 14 days post-therapy for patients treated with azithromycin with evidence (serology and/or culture) of atypical pathogens for both trials were as follows:
| Evidence of Infection | Total | Cure | Improved | Cure + Improved |
|---|---|---|---|---|
| Mycoplasma pneumoniae | 18 | 11 (61%) | 5 (28%) | 16 (89%) |
| Chlamydia pneumoniae | 34 | 15 (44%) | 13 (38%) | 28 (82%) |
| Legionella pneumophila | 16 | 5 (31%) | 8 (50%) | 13 (81%) |
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.